Tradercommunity Clickoptions Forum

[Newsagent]

PR inside: Faron Announces First Patient Dosed in BLAZE Investigator-Initiated ...

(PR-inside.com) First clinical evaluation of bexmarilimab plus nivolumab in patients with anti-PD-1-resistant solid tumors

TURKU, FI / ACCESS Newswire / October 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN) , a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that the first patient has been dosed in the Phase 1/2 BLAZE investigator-initiated trial.

The trial evaluates Faron's lead asset, bexmarilimab, in combination with the widely used anti-PD-1 checkpoint inhibitor nivolumab (OPDIVO®) in patients with metastatic non-small cell lung cancer (NSCLC) and melanoma who have developed resistance to and experienced disease progression on prior ..

https://reports.pr-inside.com/faron-ann ... 229266.htm
Copyright PR-Inside.com 2026